Standout Papers

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study 2024 202650
  1. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study (2024)
    Aditya Bardia, Ian E. Krop et al. Journal of Clinical Oncology

Immediate Impact

1 from Science/Nature 60 standout
Sub-graph 1 of 19

Citing Papers

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
2 intermediate papers

Works of Senthil Damodaran being referenced

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
2020
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Senthil Damodaran 469 249 197 72 653
Neelima Vidula 456 306 190 66 677
Akshara Singareeka Raghavendra 483 300 243 69 791
Reshma Mahtani 410 215 182 75 592
Fara Brasó‐Maristany 442 273 269 59 656
Olga Martínez‐Sáez 434 326 283 60 778
Barbara Radecka 435 289 131 57 618
Jian Zhang 366 225 157 57 684
M. Beeram 447 301 168 48 841
Matteo Clavarezza 399 133 157 46 616
Hiroyuki Yasojima 497 324 181 50 662

All Works

Loading papers...

Rankless by CCL
2026